归创通桥发布盈喜预告：2025年全年净利润同比增长近140% 营收突破10.5亿元

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. expects a significant increase in its 2025 financial performance, with net profit projected to exceed RMB 240 million, representing a year-on-year growth of approximately 139.4%, and revenue anticipated to surpass RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1][2] Group 1: Financial Performance - The company forecasts a net profit exceeding RMB 240 million for 2025, marking a substantial increase of around 139.4% compared to the previous year [1] - Expected revenue for 2025 is over RMB 1.05 billion, which indicates a year-on-year growth of approximately 34.6% [1] Group 2: Product and Market Development - The strong financial performance is attributed to robust sales growth of core products, accelerated development of overseas business, and continuous optimization of operational efficiency [1] - Key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon dilation catheter, and ZYLOX Swan venous intraluminal radiofrequency closure catheter have all seen rapid sales growth [1] - International sales revenue has more than doubled year-on-year, with increasing market penetration in key countries like Germany, France, and Italy [1] Group 3: Strategic Initiatives - The company is focusing on "innovation" and "internationalization" as core strategies to drive business layout and upgrades [2] - Several innovative products have been approved for market launch, including the ZYLOX Mammoth large lumen peripheral thrombectomy catheter and Tongqiao Feilong intracranial aneurysm embolization assist stent, which have shown positive market performance [2] - The company has expanded its sales channels to cover 83 countries and regions globally and established strategic partnerships with over 80 overseas partners [2] - A strategic acquisition of the German company Optimed was announced to enhance the company's presence in the European and global markets [2]